The low-risk osteosarcoma group displayed distinctly higher PD-L1 expression than the high-risk group (p = 0.00054; Figure 5D), indicating that the low-risk samples could be likely to respond to anti-PD-L1 therapy. The gene discussed is CD274; the disease is osteosarcoma.